Clinical Trial

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2021-09-01; most recent amendment 2026-04-22.
Status change: Not Yet Recruiting → Recruiting 2024-10-03
Status change: Recruiting → Not Yet Recruiting 2023-01-31
Trial Details
NCT Number NCT05042258
Lead Sponsor Northwestern University
Collaborators: Regeneron Pharmaceuticals
Conditions Atopic Dermatitis, Sleep Disturbance
Enrollment 40 participants
Start Date 2024-08-12
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-27